Differences

This shows you the differences between two versions of the page.

--- home:diseases:ibs [02.17.2019] – [Irritable bowel syndrome (IBS)] sallieq
+++ home:diseases:ibs [03.15.2019] – [Further research] sallieq
@@ Line 47: / Line 47: @@
 Free versus total serum 25-hydroxyvitamin D in a murine model of colitis.  (({{pubmed>long:    30710745}}))
+==== Further research ====
+Findings suggest that neither olmesartan nor other ARBs were associated with diarrhea among patients undergoing endoscopy. The spruelike enteropathy recently associated with olmesartan is likely a rare adverse effect and milder presentations are unlikely.  (({{pubmed>long:25023670}}))
+In a methotrexate-induced model of intestinal mucositis, olmesartan reduced inflammation and induced enteropathy characterized by severe diarrhea, weight loss, and reduced sucrose activity.   (({{pubmed>long:25947920}}))
+Mast cell activation syndromes   (({{pubmed>long:    28780942}}))
+Gastrointestinal (GI) symptoms are commonly reported in patients with mast cell disease.  (({{pubmed>long:    30007461}}))
+ Mast cells are located in close proximity to the vasculature, and vasoactive mediators released upon their activation can promote endothelial activation leading to blood brain barrier (BBB) dysfunction.  (({{pubmed>long:    30837844}}))
+Mast cell activation plays an important role in stress-mediated disease pathogenesis.   (({{pubmed>long:30837843}}))

home/diseases/ibs.txt · Last modified: 09.14.2022 by 127.0.0.1